Aminoglycoside susceptibility of isolates with the CTX-M (cefotaxime-hydrolyzing β-lactamase) resistance mechanism (n = 35) as their only defined β-lactam resistance mechanism, determined using CLSI, EUCAST, and FDA breakpoints. S, susceptible; I, CLSI intermediate and EUCAST susceptible increased exposure categories; R, resistant; PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin.